Silicon Canals
No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us
No Result
View All Result
Silicon Canals
No Result
View All Result

AI-based biotech startup Owkin becomes France’s new ‘unicorn’ after raising €159M from Sanofi

Vishal Singh by Vishal Singh
November 19, 2021
in (Crowd)funding, News
Owkin

Image credit: Owkin

LinkedInTwitterWhatsAppFacebook
Read this article in:

French and US-based Owkin, a startup that provides machine learning to allow medical researchers to test AI models on distributed data, has raised $180M (approx €159M) in a fresh round of funding. With a valuation of more than $1B, Owkin has now earned the status of a ‘unicorn’.

The investment was a strategic collaboration by Paris-based Sanofi, a therapeutic solutions provider. The funding will support Owkin to develop the world’s leading histology and genomic cancer database from top oncology centres.

Combining data to accelerate drug discovery

Owkin, an artificial intelligence (AI) and precision medicine company, was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and Gilles Wainrib, PhD, an academic pioneer in the field of Artificial Intelligence in biology.

Thomas Clozel explains, “Owkin’s mission is to improve patients’ lives by using our platform to discover the right treatment for every patient. We believe that the future of precision medicine lies in technologies that can unlock insights from the vast amount of patient data in hospitals and research centres in a privacy-preserving way. The future of AI to transform how we develop treatments is incredibly bright.”

The company was built on the belief that medical research should be collaborative, inclusive, and privacy-preserving. Owkin is building a global research network using federated learning, connecting data scientists, clinicians, researchers, and pharma on a research platform that keeps the data secure and preserves privacy.

As of now, Owkin has raised over $70M in funding and is now working with the largest cancer centres and pharmaceutical companies in Europe and in the US.

Aim of the collaboration

Owkin and Sanofi’s three year strategic collaboration will work towards discovering and developing programmes in four exclusive types of cancer. With an aim to optimise clinical trial design and detect predictive biomarkers, this collaboration will support Sanofi’s oncology portfolio in core areas such as lung cancer, breast cancer, and multiple myeloma.

The deal includes a $90M discovery and development partnership, plus the chance for additional milestone-based payments based on the pair’s success.

Owkin claims to have a global research network powered by federated learning to accelerate medical research in a privacy-preserving way. This research network allows data scientists to securely connect to decentralised multi-party data sets and train AI models without pooling data.

Sanofi says it will leverage the comprehensive Owkin platform to find new biomarkers, build predictive models, and predict response to treatment from multimodal patient data. As a result, this approach will complement Sanofi’s emerging strength in oncology.

Arnaud Robert, executive VP and Chief Digital Officer at Sanofi, says, “Owkin’s unique methodology, which applies AI on patient data from partnerships with multiple academic medical centres, supports our ambition to leverage data in innovative ways in R&D. We are striving to advance precision medicine and to discover innovative treatment methods with the greatest benefits for patients.”

Responsive innovation in metastatic breast cancer research

Founded in 2004 by Jean-François Dehecq and Jean-René Sautier, Sanofi is a life sciences company committed to improving access to healthcare and supporting people throughout the continuum of care. 

From prevention to treatment, Sanofi wants to transform scientific innovation into healthcare solutions in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. 

Sanofi employs more than 110,000 people across multiple countries.

Tags: biotechfundingnews
ShareTweetSendShare

Partner content | Partner with us

Germany’s Sastrify expands market reach; acquires Amsterdam-based Pengu and raises fresh funds

Amsterdam-based startups that are fundraising right now

Founders on Bootstrapping: Insight’s Farzan Najmeddin on when to bootstrap, future of work, and funding

Check out the Amsterdam startups that raised funding in November; 5 of them are hiring

Dutch-Swiss startup Cradle raises €21.9M for pioneering Generative AI in protein design

Silicon Canals | Find a job

Top news | from Amsterdam

Amsterdam’s LAYCO raises €300K to make healthcare more sustainable and accessible

Amsterdam’s ImpactPilot set to revolutionise customer success through HubSpot integration

Meet the winners of the Amsterdam Science & Innovation Award 2023

Amsterdam’s grocery app Crisp bags €35M from Adriaan Mol, Thomas Plantenga, others 

Amsterdam fintech Silverflow raises €15M to fuel its “aggressive” global expansion plans

  • About Silicon Canals
  • Partner with Silicon Canals
  • Impressum
  • Contact us
  • Sign up for our newsletter!
  • Find a job
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

X
X